On Tuesday, Shares of Twenty-First Century Fox, Inc. (NASDAQ:FOXA), lost -1.99% to $30.05, as its major comic book superhero movie “Fantastic Four” fell short of expectations at the box office in its opening weekend, The Wall Street Journal reports.
The film earned $26.2 million this past weekend, while analysts had forecast the film to bring in about $40 million, The Journal noted.
“Fantastic Four” cost about $120 million to make, The Journal added.
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming, Television, Filmed Entertainment, and Direct Broadcast Satellite Television segments.
Shares of Spirit Realty Capital, Inc. (NYSE:SRC), inclined 1.75% to $10.47, during its last trading session.
Spirit Realty Capital declared that it has released its second quarter financial and operating results for the three and six months ended June 30, 2015.
Spirit Realty Capital, Inc is a publicly traded real estate investment trust. The firm primarily acquires across the United States single tenant operationally essential real estate, which refers to generally free-standing, commercial real estate facilities where tenants conduct retail, service or distribution activities that are essential to the generation of their sales and profits.
Finally, Organovo Holdings, Inc. (NYSEMKT:ONVO), ended its last trade with -22.65% loss, and closed at $2.63, hitting its lowest level.
Organovo Holdings stated its financial results for the first quarter of fiscal 2016 ended June 30, 2015.
Recent Corporate Highlights Included:
- Celebrated the successful launch of its exVive3DTM Human Liver Tissue, with an declarement of the launch results showing about $2 million in total contract bookings as of June 9, 2015.
- Presented data on the Company’s in vitro three-dimensional kidney tissue at the 2015 Experimental Biology conference in Boston, Massachusetts, demonstrating fully human kidney proximal tubular tissues were generated that were three-dimensional, and compriseed of multiple tissue-relevant cell types arranged to recapitulate the renal tubular/interstitial interface. This breakthrough result demonstrated a proof of concept that kidney is on the way to becoming another core commercial tissue for Organovo.
- Declared a partnership with L’Oreal USA, wherein L’Oreal’s U.S.-based global Technology Incubator and Organovo will leverage Organovo’s proprietary NovoGen Bioprinting Platform and L’Oreal’s expertise in skin engineering to develop 3D printed skin tissues for product evaluation and other areas of advanced research, marking the first-ever application of Organovo’s groundbreaking technology within the beauty industry.
- Raised $46 million through the sale of about 10.8 million shares of common stock in an underwritten secondary offering focused primarily on institutional investors. Jefferies LLC and Piper Jaffray & Co. acted as joint book-running managers for this offering.
- Declared the hiring of Paul Gallant as the Company’s General Manager of the in vitro tissue service and product business. Mr. Gallant brings more than 20 years of administration and R&D experience in the drug discovery industry, where he most recently served as chief operating officer for DiscoveRx, a global scientific product and services company. The Company plans to draw upon Mr. Gallant’s experience in advancing new technology platforms in partnershipwith pharmaceutical companies, contract research organizations and academic institutions to assist it with developing and executing strategies for capturing market share and otherwise growing its in vitro business.
Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
